Article Dans Une Revue European Journal of Endocrinology Année : 2022

An impressive response with larotrectinib in a patient with a papillary thyroid carcinoma harboring an SQSTM1-NTRK1 fusion

Résumé

NTRK rearrangements represent a very rare genomic abnormality among all cancers but can be detected in thyroid cancer with a non-negligible frequency of 2%. Dramatic clinical responses to therapies targeting NTRK chimeric proteins are now well described in the literature. SQSTM1-NTRK1 fusions have not yet been described in a full clinical case report. We report a patient with a papillary thyroid carcinoma harboring this unique rearrangement, with an impressive clinical and radiologic response to larotrectinib, a highly specific inhibitor.

Fichier non déposé

Dates et versions

hal-04074311 , version 1 (19-04-2023)

Identifiants

Citer

Sophie Bargas, Anne Mc Leer, Julie Mondet, Olivier Chabre, Mathieu Laramas. An impressive response with larotrectinib in a patient with a papillary thyroid carcinoma harboring an SQSTM1-NTRK1 fusion. European Journal of Endocrinology, 2022, 186 (4), pp.K5-K8. ⟨10.1530/EJE-21-0509⟩. ⟨hal-04074311⟩

Collections

44 Consultations
0 Téléchargements

Altmetric

Partager

  • More